2018 Biotechnology Awards

16 GHP / Biotechnology Awards 2018 , Peter Feldman, Arbor Life Labs CEO and Chief Trichologist Arbor Life Labs strives to support consumers’ growing demand for the extraordinary healing power of nature using drug- free, all natural and clean-label products by bridging the gaps between traditional healing arts and rigorous science in human biology. Peter discusses the firm’s focus on its hair loss treatment and how it works to ensure that the very highest standards are met to satisfy the needs of its clients. “Here at Arbor Life Labs our primary research currently focuses on molecular markers influencing the integumentary system with emphasis on hair growth. Our lead product targets the $8B EU and US and the $16B Asian Hair Loss market with an efficacy superiority over the market leading drugs and natural products. Arbor has been able to secure 47 health claims, approved by Health Canada including Alopecia. Arbor’s lead product is certified as clean label, drug-free, vegan, gluten free and non-GMO to meet changing market demands. Arbor’s hair loss BI180018 Best Development Stage Biotech Company – Canada & Award for Excellence in Regenerative Therapeutics Arbor Life Labs is amarket disrupting biotech company that uses natural ingredients to correct common chronic, aging and degenerative health disorders by activating stem cells and regulatingmolecular pathways, such as gene expressions, hormones and signalling to normalize cell, tissue and organ functions. We invited Peter Feldman, Arbor Life Labs’ CEO and Chief Trichologist, to tell us more about the firmand how it came to win this prestigious award. products are currently available under the brand Replenology.” “With 60% of men and 40% of women experiencing hair loss and the leading approved drug having less than 30% efficacy, there is an unmet need for high-efficacy non-surgical solutions. The market is experiencing a rapid change in consumer behaviour and demographics demanding clean-label, drug-free solutions with strong scientific validation. As a firm we are poised to meet these changing demands.” There are more than 30 published molecular pathways associated with hair growth and loss. Most solutions inhibit only dihydrotestosterone(DHT) with limited results. A systematic review of studies of the leading hair loss drug accounting for more than 5,000 studied subjects, reported an efficacy of less than 30%. Dermatologists acknowledge current hair loss solutions do not effectively meet the medical need. Arbor is addressing this unmet need by targeting 21 molecular pathways implicated in hair growth and loss to yield an efficacy superiority over the market leading drugs. Its patents pending create a significant competitive barrier and provide a platform for broad expansion into other regenerative therapeutic areas associated with healthy aging, as Peter explains. “Our intellectual property modulates molecular markers with natural ingredients with a high degree of specificity, efficacy and safety. Many of our competitors in natural products cannot explain how their products work or demonstrate efficacy. Our pharmaceutical competitors have products that are focused on one specific biologic action. The science has been widely published that hair loss is caused by multiple biological actions, and Arbor has developed the most comprehensive hair loss solution to-date.” “Arbor’s proprietary intellectual property is a broad regenerative and healthy-aging platform addressing multiple cell, tissue and organ types”